Home News Vuity meets primary endpoint goals for near visual acuity improvement

Vuity meets primary endpoint goals for near visual acuity improvement

68
0


September 01, 2022

1 min watch


Source/Disclosures

Source:

McCabe CM. GEMINI 1 & 2 pooled phase 3 studies safety and efficacy: AGN-190584 primary and key secondary endpoints. Presented at: Women in Ophthalmology Summer Symposium; Aug. 25-28, 2022; Monterey, California (hybrid meeting).


Disclosures:
McCabe reports being a consultant to and speaker for Allergan.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Cathleen M. McCabe, MD, discusses trial data for Vuity in the correction of presbyopia.

The study results showed that Vuity (pilocarpine hydrochloride ophthalmic solution 1.25%, Allergan) met primary endpoint goals for 3-line best-corrected near visual acuity improvement without a loss of more than 5 letters in distance acuity.



McCabe2_OG



“There was also a large percentage of patients who achieved 20/40 or better near visual acuity at the 30-day, 1-hour and 3-hour endpoints, McCabe said.

Previous articleYoga With Adriene Announces Partnership With Manduka
Next articleGet Moving! Any Sports Can Lower Seniors’ Odds of Early Death